Japanese biopharmaceutical company Y's Therapeutics has completed patient enrollment for its phase II clinical trial of its compound YSPSL for prevention of delayed graft function (DGF) in kidney transplant patients.
Cambus Medical currently employs 25 people at the Spiddal operation.
The company recently extended the plant at Baile an tSagairt industrial estate, tripling its production capacity while providing a dedicated 4,000 sq ft space to support R&D and new product introduction.
Barry Comerford, managing director comments: “To enable Cambus Medical to compete within the global marketplace, our entire focus to date has centred on creating advanced process technologies and a management and engineering infrastructure which can support rapid growth of our business while providing our customers with the very highest levels of customer service and technical support”.
Udaras na Gaeltachta chief executive officerPadraig O’ hAolain has welcomed the announcement, stating: “Cambus Medical meets all of our investment strategy criteria in that its products have a strong presence in the growing medical device sector, it has cutting edge technology, is export-orientated and provides quality jobs for third-level graduates.”